Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Changes To Part D Protected Classes Uniformly Opposed At House Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

In a hearing on CMS’ proposed Medicare Part D rule, members of the Energy & Commerce Health Subcommittee agreed that the potential cost savings to Medicare through its plan to remove antidepressants, antipsychotics and immunosuppressants from Part D “protected class” status do not outweigh the downside for beneficiaries.

You may also be interested in...



Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents

Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.

Medicare Part D Price Inflation Rebates Won’t Mean As Much In Inflationary Times

Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.

Manufacturer Donations To Copay Charities: Profitability Underscores Kickback Concerns – Study

Department of Justice anti-kickback expert seeks to quantify the potential for manufacturers to benefit from donations to independent copay assistances organizations.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS076881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel